Definition:
The Lipid-Lowering Agents market covers drugs to treat hyperlipidemia or dyslipidemia. These metabolic disorders are characterized by high levels of lipids, such as fats, cholesterol, or triglycerides, or lipoproteins in the blood. Different drug classes are included: statins, PCSK9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, as well as combinations thereof.
Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).
Company examples: Merck & Co., AstraZeneca, Viatris
Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.
Most recent update: Jun 2024
Source: Statista Market Insights
Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.
Most recent update: Mar 2024
The Lipid-Lowering Agents market in Guinea has been experiencing significant growth in recent years.
Customer preferences: The demand for lipid-lowering agents has been increasing in Guinea due to the rise in the prevalence of cardiovascular diseases. The aging population and unhealthy lifestyles have contributed to the increase in the number of people suffering from cardiovascular diseases. As a result, there has been an increase in demand for lipid-lowering agents in Guinea.
Trends in the market: The trend in the Lipid-Lowering Agents market in Guinea is towards the use of generic drugs. The high cost of branded drugs has made it difficult for many people to afford them. As a result, many people have turned to generic drugs, which are more affordable. The availability of generic drugs has also increased, making it easier for people to access them.Another trend in the market is the use of combination therapy. Combination therapy involves the use of two or more lipid-lowering agents to achieve better results. This approach has become more popular in Guinea as it has been proven to be more effective in reducing cholesterol levels.
Local special circumstances: One of the special circumstances in Guinea is the lack of access to healthcare facilities in rural areas. This has made it difficult for people in rural areas to access lipid-lowering agents. The government has been working to address this issue by building more healthcare facilities in rural areas and increasing the availability of medication.Another special circumstance is the lack of awareness about cardiovascular diseases and the importance of lipid-lowering agents. Many people in Guinea are not aware of the risks associated with cardiovascular diseases, and as a result, they do not take the necessary measures to prevent them. The government and other organizations have been working to raise awareness about these issues.
Underlying macroeconomic factors: The economic growth in Guinea has contributed to the growth of the Lipid-Lowering Agents market. The increase in per capita income has made it possible for more people to afford lipid-lowering agents. The government has also been working to improve the healthcare system, which has increased access to healthcare facilities and medication.In conclusion, the Lipid-Lowering Agents market in Guinea has been growing due to the increase in demand for lipid-lowering agents, the use of generic drugs, and the use of combination therapy. The lack of access to healthcare facilities in rural areas and the lack of awareness about cardiovascular diseases are some of the special circumstances that have affected the market. The economic growth in Guinea has also contributed to the growth of the market.
Most recent update: Jun 2024
Source: Statista Market Insights
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Notes: Based on data from IMF, World Bank, UN and Eurostat
Most recent update: Sep 2024
Source: Statista Market Insights